• 1
    PE C. The limiting factor in the glycaemic management of Type I and Type II Diabetes. Diabetologia 2002; 45: 937948.
  • 2
    Shu C, He J. The long-term observation of the transplantation of encapsulated rat islets to the diabetic mice. Biomater Artif Cells Immobiliz Biotechnol 1993; 21: 8589.
  • 3
    Group U. Intensive blood-glucose control with sylhonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. Lancet 1998; 352: 837853.
  • 4
    Shapiro AM, Ricordi C, Hering BJ et al. International trial of the Edmonton protocol for islet transplantation. N Engl J Med 2006; 355: 13181330.
  • 5
    Hering BJ, Kandaswamy R, Ansite JD et al. Single-donor, marginal-dose islet transplantation in patients with type 1 diabetes. JAMA 2005; 293: 830835.
  • 6
    DeFronzo RA, Ratner RE, Han J, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 2005; 28: 10921100.
  • 7
    Poon T, Nelson P, Shen L et al. Exenatide improves glycemic control and reduces body weight in subjects with type 2 diabetes: A dose-ranging study. Diabetes Technol Ther 2005; 7: 467477.
  • 8
    Kendall DM, Riddle MC, Rosenstock J et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 2005; 28: 10831091.
  • 9
    Ghofaili KA, Fung M, Ao Z et al. Effect of exenatide on beta cell function after islet transplantation in type 1 diabetes. Transplantation 2007; 83: 2428.
  • 10
    Robertson RP. Consequences on beta-cell function and reserve after long-term pancreas transplantation. Diabetes 2004; 53: 633644.
  • 11
    Ryan EA, Shandro T, Green K et al. Assessment of the severity of hypoglycemia and glycemic lability in type 1 diabetic subjects undergoing islet transplantation. Diabetes 2004; 53: 955962.
  • 12
    Shapiro AM, Lakey JR, Ryan EA et al. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N Engl J Med 2000; 343: 230238.
  • 13
    Grading diabetic retinopathy from stereoscopic color fundus photographs—an extension of the modified Airlie House classification. ETDRS report number 10. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology 1991; 98(5 Suppl): S786S806.
  • 14
    Ricordi C, Lacy PE, Finke EH, Olack BJ, Scharp DW. Automated method for isolation of human pancreatic islets. Diabetes 1988; 37: 413420.
  • 15
    Barbaro B, Salehi P, Wang Y et al. Improved human pancreatic islet purification with the refined UIC-UB density gradient. Transplantation 2007; 84: 12001203.
  • 16
    Ricordi C, Gray DW, Hering BJ et al. Islet isolation assessment in man and large animals. Acta Diabetol Lat 1990; 27: 185195.
  • 17
    Yang H, Acker J, Chen A, McGann L. In situ assessment of cell viability. Cell Transplant 1998; 7: 443451.
  • 18
    Avila JG, Tsujimura T, Oberholzer J et al. Improvement of pancreatic islet isolation outcomes using glutamine perfusion during isolation procedure. Cell Transplant 2003; 12: 877881.
  • 19
    Tsujimura T, Kuroda Y, Kin T et al. Human islet transplantation from pancreases with prolonged cold ischemia using additional preservation by the two-layer (UW solution/perfluorochemical) cold-storage method. Transplantation 2002; 74: 16871691.
  • 20
    Teuscher AU, Kendall DM, Smets YF, Leone JP, Sutherland DE, Robertson RP. Successful islet autotransplantation in humans: Functional insulin secretory reserve as an estimate of surviving islet cell mass. Diabetes 1998; 47: 324330.
  • 21
    Pacini G, Bergman RN. MINMOD: A computer program to calculate insulin sensitivity and pancreatic responsivity from the frequently sampled intravenous glucose tolerance test. Comp Methods Prog Biomed 1986; 23: 113122.
  • 22
    Kaplan B, West P, Neely H et al. Use of chronic IL-2 receptor blockade in an islet transplant recipient. Clin Transplant 2007 (in press).
  • 23
    Li Y, Hansotia T, Yusta B, Ris F, Halban PA, Drucker DJ. Glucagon-like peptide-1 receptor signaling modulates beta cell apoptosis. J Biol Chem 2003; 278: 471478.
  • 24
    Tourrel C, Bailbe D, Meile MJ, Kergoat M, Portha B. Glucagon-like peptide-1 and exendin-4 stimulate beta-cell neogenesis in streptozotocin-treated newborn rats resulting in persistently improved glucose homeostasis at adult age. Diabetes 2001; 50: 15621570.
  • 25
    Xu G, Stoffers DA, Habener JF, Bonner-Weir S. Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats. Diabetes 1999; 48: 22702276.
  • 26
    Vally M, Seenu S, Pillarisetti S. Emerging peptide therapeutics for inflammatory diseases. Current Pharm Biotechnol 2006; 7: 241246.
  • 27
    Larsen CM, Faulenbach M, Vaag A et al. Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N Engl J Med 2007; 356: 15171526.
  • 28
    Kreymann B, Williams G, Ghatei MA, Bloom SR. Glucagon-like peptide-1 7–36: A physiological incretin in man. Lancet 1987; 2: 13001304.
  • 29
    Mojsov S, Weir GC, Habener JF. Insulinotropin: Glucagon-like peptide I (7–37) co-encoded in the glucagon gene is a potent stimulator of insulin release in the perfused rat pancreas. J Clin Invest 1987; 79: 616619.
  • 30
    Ionut V, Liberty IF, Hucking K et al. Exogenously imposed postprandial-like rises in systemic glucose and GLP-1 do not produce an incretin effect, suggesting an indirect mechanism of GLP-1 action. Am J Physiology 2006; 291: E779785.